Related Experiment Video

Updated: May 9, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Perifosine--a new option in treatment of acute myeloid leukemia?

Janusz Krawczyk1, Niamh Keane, Ronan Swords

  • 1Galway University Hospital , Newcastle Rd, Galway , Ireland jkrawczyk@pro.onet.pl.

Expert Opinion on Investigational Drugs
|August 13, 2013
PubMed
Abstract

Insights

Perifosine, an Akt inhibitor, shows promise in leukemia treatment. While preclinical data is encouraging, further clinical trials are needed to confirm its efficacy and optimal use in patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Perifosine is a novel oral Akt inhibitor with cytotoxic potential in leukemia models.
  • It demonstrates synergistic effects with other targeted agents.
  • The phosphatidylinositol-3 kinase (PI3K)/Akt pathway is crucial in cancer and leukemias.

Purpose of the Study:

  • To review the mechanism of action, development, and properties of perifosine.
  • To summarize preclinical and clinical evidence for perifosine in leukemia therapy.
  • To evaluate the therapeutic potential of perifosine in well-designed clinical trials.

Main Methods:

  • Review of in vivo and in vitro studies on perifosine.
  • Summary of clinical trial data regarding efficacy and side effects.
  • Discussion of the PI3K/Akt pathway's role in leukemia.

Main Results:

  • Perifosine exhibits independent cytotoxic potential and synergizes with other agents in preclinical leukemia models.
  • The drug has a favorable safety and tolerability profile.
  • Clinical trial evidence in leukemias is currently limited.

Conclusions:

  • Perifosine is a safe and tolerable Akt inhibitor.
  • Preclinical data suggest significant therapeutic potential for leukemia treatment.
  • Further clinical trials are essential to establish perifosine's role and optimal regimen in leukemia therapy.

More Related Videos

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...